Clinical trials: Covid19 Vaccine
COVID-19, Respiratory Disease
Health Communication to Influence COVID-19 Vaccination Intent and Message Propagation
This is a randomised controlled experiment in the form of a web based survey study which randomly exposes participants to different forms of public health messages, after which participants will be assessed on their intent to…
- Conditions
- COVID-19, Respiratory Disease, Vaccine Refusal, Infectious Disease
- Trial name
- CONVINCE (NCT05244356)
- Testing
- Health message exposure
- Where
- Malaysia
- Volunteers
- 5,784 people, healthy volunteers welcome
- Sponsor
- Clinical Research Centre, Malaysia
SARS-CoV-2
A Study to Evaluate the Immunogenicity and Safety of Omicron Variant Vaccines in Comparison With mRNA-1273 Booster Vaccine for COVID-19
This is a 2-part study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.529 and mRNA-1273.214 administered as a booster dose.
- Trial name
- NCT05249829
- Testing
- mRNA-1273.529, mRNA-1273, mRNA-1273.214
- Where
- 29 sites in United Kingdom
- Volunteers
- 3,548 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
SARS (Severe Acute Respiratory Syndrome)
Sisonke (Together): OPEN LABEL TRIAL COVID-19
To monitor the effectiveness of the single-dose Ad26.COV2.S COVID-19 vaccine among health care workers (HCW) in South Africa
- Trial name
- Sisonke (NCT04838795)
- Testing
- To monitor the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine
- Where
- 31 sites in South Africa
- Volunteers
- 477,102 people, healthy volunteers welcome
- Sponsor
- Wits Health Consortium (Pty) Ltd
COVID-19, SARS-COV-2 Infection
A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age
This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a group that receives a vaccine that doesn't contain an ingredient to protect…
- Trial name
- NCT07300839
- Testing
- BNT162b2 Vaccine
- Where
- 196 sites in United States
- Volunteers
- 5,240 people, healthy volunteers welcome
- Sponsor
- BioNTech SE
COVID-19 Pandemic, COVID-19 Vaccines
UNAIR Inactivated COVID-19 Vaccine as Heterologue Booster (Immunobridging Study)
This is an observer blind randomized controlled trial study to evaluate the humoral immunogenicity profile - neutralizing antibody - after 28 days following vaccination with Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell…
- Trial name
- NCT05918939
- Testing
- Vaksin Merah Putih - UA SARS-CoV-2 (Vero Cell Inactivated) 5 µg, CoronaVac Biofarma COVID-1 9 Vaccine 3 µg
- Where
- Indonesia
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Dr. Soetomo General Hospital
COVID-19
A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers
This is a phase II, observer-blind, multiple-centre, randomized, placebo-controlled study to evaluate the immunogenicity, safety, tolerability and lot consistency of 2 doses of UB-612 vaccine in adolescent, younger and elderly…
- Trial name
- NCT04773067
- Testing
- UB-612
- Where
- 12 sites in Taiwan
- Volunteers
- 3,877 people, healthy volunteers welcome
- Sponsor
- United Biomedical Inc., Asia
COVID-19
Project REMOTE (REimagining Measurements and Operations of Translational Endpoints)
This trial is designed to assess immunological biomarkers measured from blood samples that can be used to reliably predict how well vaccines work against symptomatic COVID-19 as well as to evaluate the feasibility of remote…
- Trial name
- REMOTE (NCT06776367)
- Testing
- Remote study participation and self-collection of specimens, Traditional clinical trial participation with clinician-collected specimens
- Where
- 16 sites in United States
- Volunteers
- 1,753 people, healthy volunteers welcome
- Sponsor
- Biomedical Advanced Research and Development Authority
COVID-19
Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine
This is a randomized, observer-blind, placebo-controlled study, for evaluation of safety and immunogenicity of heterologous prime-boost immunization of recombinant COVID-19 vaccine (adenovirus type-5 vector) and RBD-based protein…
- Trial name
- NCT04833101
- Testing
- recombinant Ad5 vectored COVID-19 vaccine, RBD-based protein subunit vaccine (ZF2001) against COVID-19, trivalent split influenza vaccine
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
SARS-CoV-2
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT06354998
- Testing
- Investigational mRNA-1273.815, Licensed Spikevax Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
COVID 19 Vaccine
Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers
The disease promoted by coronavirus (COVID-19) is caused by Severe Acute Respiratory Syndrome (SARS) caused by Coronavirus type 2 (CoV2), being the first cases identified in December 2019 in China after exposure to the animal…
- Trial name
- ProBCG (NCT04659941)
- Testing
- BCG vaccine, 0.9% sodium chloride (NaCl) saline solution
- Where
- Brazil
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio de Janeiro
COVID-19
Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.
IIBR-100 (VSV-ΔG) is a self-propagating live virus vaccine that contains the spike protein of the Wuhan wild-type SARS-CoV-2 virus.
- Trial name
- BRILIFE002 (NCT04990466)
- Testing
- IIBR-100, Active Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- NeuroRx, Inc.
Covid19
To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2
To evaluate the safety and immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as booster vaccine for COVID-19 in healthy adults who have received 2 doses of BNT162b2
- Trial name
- NCT05200741
- Testing
- DelNS1-2019-nCoV-RBD-OPT1
- Where
- Hong Kong
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- The University of Hong Kong
Influenza
An Efficacy, Immunogenicity and Safety Study Investigating an Adjuvanted SARS-CoV-2 Influenza Vaccine to Protect Against COVID-19 in Adults Over Aged 18 Years-old and Older
The primary efficacy objective is to demonstrate the efficacy of aCoV2 versus a placebo to prevent the first occurrence of virologically-confirmed symptomatic COVID 19 according to the European Centre for Disease Prevention and…
- Trial name
- NCT04806529
- Testing
- Adjuvanted SARS-CoV-2 Subunit vaccine (aCoV2), Comparator
- Volunteers
- healthy volunteers welcome
- Sponsor
- Seqirus
Vaccination Refusal, COVID-19
COVID-19 Vaccine Uptake Trial
The goal of this study is to assess the best COVID-19 vaccine uptake strategy among students, staff and household members that have not been vaccinated.
- Trial name
- NCT05419232
- Testing
- Short Message Service (SMS) + Website Link Strategy, Phone Call with Peer Strategy
- Where
- 8 sites in United States
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
COVID-19 Vaccine
A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19
The purpose of this study is to assess the safety, tolerability, and immunogenicity of booster dose of vaccine in participants who are generally healthy or with stable pre-existing health conditions.
- Trial name
- NCT05197153
- Testing
- Half dose of MVC-COV1901, Full dose of MVC-COV1901, AZD1222
- Where
- 4 sites in Taiwan
- Volunteers
- 804 people, healthy volunteers welcome
- Sponsor
- Medigen Vaccine Biologics Corp.
COVID-19
Safety, and Immunogenicity Study of the Recombinant Two-component COVID-19 Vaccine (CHO Cell)
Part 1: Primary Vaccination in Adults Part 1 will evaluate the safety and immunogenicity of the recombinant two component COVID-19 vaccine (CHO cell) (ReCOV for short) in adults aged 18 years and older, when administered as 2…
- Trial name
- ReCOV (NCT05084989)
- Testing
- Part1:Recombinant two-component COVID-19 vaccine (CHO cell), Part2: Recombinant two-component COVID-19 vaccine (CHO cell), Part2: COVID-19 Vaccine, mRNA
- Where
- Philippines
- Volunteers
- 948 people, healthy volunteers welcome
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
Trust
Novelty, Conformity and Trust in COVID-19 Vaccines
Despite their established benefits as public measures, vaccines continue to be treated with suspicion by many people, in the US and other parts of the world (Larson et al. 2014; Olive et al. 2018; Lazarus et al. 2020).
- Trial name
- NCT04693689
- Testing
- RNA vaccine, 20% adoption rate, 40% adoption rate
- Where
- United States
- Volunteers
- 35,180 people, healthy volunteers welcome
- Sponsor
- National University of Singapore
SARS-CoV-2
EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19
This study is clinical trial (intervention study with external comparison group) to test vaccination with reduced dose (half dose) of ChAdOx1 nCoV-19 (AZD1222), in a 2-dose schedule with an interval of 8 weeks, including all…
- Trial name
- NCT05059106
- Testing
- Half dose of ChAdOx1 nCoV-19 (AZD1222), Standard dose of ChAdOx1 nCoV-19 (AZD1222)
- Where
- Brazil
- Volunteers
- 29,637 people, healthy volunteers welcome
- Sponsor
- Federal University of Espirito Santo
COVID-19 (Healthy Volunteers)
Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19)
This study is to assess the safety, reactogenicity and immunogenicity of a SK SARS-CoV-2 recombinant protein subunit vaccine (NBP2001) in healthy adults.
- Trial name
- NCT04760743
- Testing
- NBP2001 adjuvanted with alum (RBD 30μg/dose), NBP2001 adjuvanted with alum (RBD 50μg/dose), Normal Saline
- Where
- 2 sites in South Korea
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- SK Bioscience Co., Ltd.
COVID-19 Acute Respiratory Distress Syndrome, Immunosuppression
Booster Dose of COVID-19 Vaccine for Kidney Transplant Recipients Without Adequate Humoral Response
Introduction: Inadequate antibody response to mRNA SARS-CoV-2 vaccination has been described among kidney transplant recipients.
- Trial name
- WHO (NCT04961229)
- Testing
- The Pfizer mRNA-based BNT162b2 vaccine
- Volunteers
- 504 people
- Sponsor
- dafna yahav
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.